Finance

Lists
NOT:ETR
Novartis
၁၄၅.၈၀ €
-၀.၄၁%
(-၀.၆၀) 1D
နို ၅, GMT+၁ ၁၂:၀၇:၂၈  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOT...
Open
၁၄၆.၈၄ €
High
၁၄၇.၀၀ €
Low
၁၄၅.၄၈ €
Mkt. cap
ဋေ ၂.၇၃ သ
Avg. vol.
၅.၄၆ ထောင်
Volume
၂.၀၈ ထောင်
52-wk high
၁၄၇.၀၀ €
52-wk low
၁၀၇.၀၀ €
No. of employees
၈ သောင်း
Open
၁၄၆.၈၄ €
High
၁၄၇.၀၀ €
Low
၁၄၅.၄၈ €
Mkt. cap
ဋေ ၂.၇၃ သ
Avg. vol.
၅.၄၆ ထောင်
Volume
၂.၀၈ ထောင်
52-wk high
၁၄၇.၀၀ €
52-wk low
၁၀၇.၀၀ €
No. of employees
၈ သောင်း
News stories
From web sources and news partners
WSJ
WSJ
·
ပြီးခဲ့သည့် ၆ နာရီ
Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit
GuruFocus
GuruFocus
·
ပြီးခဲ့သည့် ၁၃ နာရီ
Novartis AG (NVS) Shares Surge 3.6% -- What GF Score of 82 Tells Investors
Traders Union
Traders Union
·
ပြီးခဲ့သည့် ၁၇ နာရီ
What's behind Novartis's latest 3.3% stock surge?
TradingKey
TradingKey
·
ပြီးခဲ့သည့် ၁၈ နာရီ
Novartis AG Stock (NVS) Moved Up by 3.34% on Nov 4: A Full Analysis
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis
CEOVasant Narasimhan
Employees၇.၅၃ သောင်း
Founded၁၉၉၆ မတ် ၇
Headquartersဘေဆဲလ်, Basel City, ဆွစ်ဇာလန်
Sector-
Industry-
Last report
၂၀၂၆ အောက် ၂၇
Fiscal period
Q3 2026
၂.၄၆ US$ / ၂.၂၆ US$
+၈.၆၃%beat
Revenue / Est. (USD)
ဋေ ၁.၅၀ ထ / ဋေ ၁.၄၆ ထ
+၃.၂၅%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
ဋေ ၁.၃၉ ထ
ဋေ ၁.၃၅ ထ
ဋေ ၁.၅၀ ထ
ဋေ ၁.၅၀ ထ
Cost of goods sold
၃၅၄.၂၀ ဋေ
၃၄၃.၈၀ ဋေ
၃၆၇.၈၀ ဋေ
၃၅၇.၃၀ ဋေ
Cost of revenue
၃၅၄.၂၀ ဋေ
၃၄၃.၈၀ ဋေ
၃၆၇.၈၀ ဋေ
၃၅၇.၃၀ ဋေ
Research and development expenses
၂၈၃.၇၀ ဋေ
၂၇၈.၅၀ ဋေ
၂၇၃.၉၀ ဋေ
၂၉၇.၈၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၃၄၃.၆၀ ဋေ
၃၁၃.၇၀ ဋေ
၃၂၃.၁၀ ဋေ
၃၀၇.၈၀ ဋေ
Operating expense
၆၄၆.၃၀ ဋေ
၅၉၆.၄၀ ဋေ
၆၀၉.၇၀ ဋေ
၆၃၀.၆၀ ဋေ
Total operating expenses
ဋေ ၁.၀၀ ထ
၉၄၀.၂၀ ဋေ
၉၇၇.၅၀ ဋေ
၉၈၇.၉၀ ဋေ
Operating income
၃၈၅.၅၀ ဋေ
၄၁၂.၂၀ ဋေ
၅၁၇.၆၀ ဋေ
၅၁၅.၀၀ ဋေ
Other non operating income
-၁၃.၀၀ ကုဋေ
၄.၀၀ သန်း
၁.၉၀ ကုဋေ
-၁.၄၀ ကုဋေ
EBT including unusual items
၃၂၁.၈၀ ဋေ
၃၈၃.၉၀ ဋေ
၄၂၆.၉၀ ဋေ
၁၃၁.၇၀ ဋေ
EBT excluding unusual items
၃၄၉.၂၀ ဋေ
၃၇၈.၀၀ ဋေ
၄၇၃.၁၀ ဋေ
၄၆၆.၅၀ ဋေ
Income tax expense
၈၁.၄၀ ကုဋေ
၆၈.၃၀ ကုဋေ
၁၀၁.၂၀ ဋေ
၁၂.၁၀ ကုဋေ
Effective tax rate
၂၅.၃၀%
၁၇.၇၉%
၂၃.၇၁%
၉.၁၉%
Other operating expenses
၁၉.၀၀ ကုဋေ
၄.၂၀ ကုဋေ
၁၂.၇၀ ကုဋေ
၂၅.၀၀ ကုဋေ
Net income
၂၄၀.၉၀ ဋေ
၃၁၅.၆၀ ဋေ
၃၂၆.၄၀ ဋေ
၁၂၀.၂၀ ဋေ
Net profit margin
၁၇.၃၈%
၂၃.၃၄%
၂၁.၈၃%
၈.၀၀%
Earnings per share
၂.၀၃
၁.၉၉
၂.၄၁
၂.၄၆
Interest and investment income
၃၇.၃၀ ကုဋေ
-
-
-
Interest expense
-၃၀.၄၀ ကုဋေ
-၃၄.၃၀ ကုဋေ
-၄၆.၂၀ ကုဋေ
-၄၆.၈၀ ကုဋေ
Net interest expenses
၆.၉၀ ကုဋေ
-၃၄.၃၀ ကုဋေ
-၄၆.၂၀ ကုဋေ
-၄၆.၈၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၄၉၅.၆၀ ဋေ
၅၂၃.၈၀ ဋေ
၆၂၉.၉၀ ဋေ
၆၃၈.၂၀ ဋေ
Gain or loss from assets sale
၈.၀၀ ကုဋေ
-၁၅.၉၀ ကုဋေ
-၂၄.၇၀ ကုဋေ
၉.၄၀ ကုဋေ
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ